Home > Insider Trading > Filing (0001104659-22-037649)

Filing Details

Accession Number:: 0001104659-22-037649
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-03-24 20:07:37
Reporting Period:: 2022-03-22

Accepted Time:: 2022-03-24 20:07:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1802665	Harmony Biosciences Holdings Inc.	HRMY	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1602402	Jack Nielsen	C/O Harmony Biosciences Holdings, Inc. 630 W. Germantown Pike, Suite 215 Plymouth Meeting PA 19462		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-03-22	819	$50.13	39,866	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-03-22	5,757	$50.13	4,280,345	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-03-23	1,344	$50.25	38,522	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-03-23	9,439	$50.25	4,270,906	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-03-24	2,359	$50.12	36,163	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-03-24	16,576	$50.12	4,254,330	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $51.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4.